PMID- 25186131
OWN - NLM
STAT- MEDLINE
DCOM- 20150723
LR  - 20220408
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 346
IP  - 1-2
DP  - 2014 Nov 15
TI  - IncobotulinumtoxinA (Xeomin(R)) injected for blepharospasm or cervical dystonia 
      according to patient needs is well tolerated.
PG  - 116-20
LID - S0022-510X(14)00517-6 [pii]
LID - 10.1016/j.jns.2014.08.004 [doi]
AB  - Typically, botulinum toxin injections for blepharospasm or cervical dystonia (CD) 
      are administered at approximately 3-month intervals, reflecting concerns that 
      shorter intervals might increase the risk of adverse events (AEs) and development 
      of neutralizing antibodies. These post-hoc analyses investigated flexible 
      incobotulinumtoxinA (Xeomin(R)) injection intervals (6-20 weeks) in patients with 
      blepharospasm or CD. Patients received up to 6 injections at intervals >/= 6 weeks, 
      as determined by physician assessment upon patient request. The blepharospasm 
      study permitted flexible doses (</= 50 U/eye). The CD study employed fixed dosing 
      using incobotulinumtoxinA 120 U, 240 U, or placebo for the first treatment 
      followed by subsequent randomization to 120 U or 240 U for the extension period. 
      Standard safety assessments were performed. Intervals <12 weeks were employed in 
      207 of 461 (44.9%) treatment cycles for blepharospasm and in 369 of 821 (44.9%) 
      treatment cycles for CD. The most frequent AEs were eyelid ptosis and dry eyes in 
      patients treated for blepharospasm, and dysphagia and neck pain in patients with 
      CD. AE frequency and severity were similar for intervals <12 weeks and >/= 12 weeks 
      in both studies. In conclusion, repeated incobotulinumtoxinA injections employing 
      flexible intervals (6-20 weeks) per patients' needs were well tolerated. No 
      additional safety concerns were observed with <12-week intervals compared with >/= 
      12-week intervals.
CI  - Copyright (c) 2014 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Evidente, Virgilio Gerald H
AU  - Evidente VG
AD  - Movement Disorders Center of Arizona, 9590 E. Ironwood Square Drive, Suite 225, 
      Scottsdale, AZ 85258, USA. Electronic address: vevidente@movementdisorders.us.
FAU - Truong, Daniel
AU  - Truong D
AD  - The Parkinson's and Movement Disorder Institute, 9940 Talbert Avenue, Fountain 
      Valley, CA 92708, USA.
FAU - Jankovic, Joseph
AU  - Jankovic J
AD  - Department of Neurology, Baylor College of Medicine, Smith Tower, 18th Floor, 
      6550 Fannin, Suite 1801, Houston, TX 77030, USA.
FAU - Comella, Cynthia L
AU  - Comella CL
AD  - Department of Neurological Sciences, Rush University Medical Center, 1725 West 
      Harrison Street Suite 755, Chicago, IL 60612, USA.
FAU - Grafe, Susanne
AU  - Grafe S
AD  - Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt, Germany.
FAU - Hanschmann, Angelika
AU  - Hanschmann A
AD  - Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt, Germany.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140810
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
RN  - EC 3.4.24.69 (incobotulinumtoxinA)
SB  - IM
MH  - Blepharospasm/*drug therapy
MH  - Botulinum Toxins, Type A/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Neuromuscular Agents/*therapeutic use
MH  - Outcome Assessment, Health Care
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Torticollis/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Blepharospasm
OT  - Botulinum toxin
OT  - Cervical dystonia
OT  - IncobotulinumtoxinA
OT  - Patient satisfaction
OT  - Xeomin(R)
EDAT- 2014/09/05 06:00
MHDA- 2015/07/24 06:00
CRDT- 2014/09/05 06:00
PHST- 2014/03/28 00:00 [received]
PHST- 2014/07/22 00:00 [revised]
PHST- 2014/08/04 00:00 [accepted]
PHST- 2014/09/05 06:00 [entrez]
PHST- 2014/09/05 06:00 [pubmed]
PHST- 2015/07/24 06:00 [medline]
AID - S0022-510X(14)00517-6 [pii]
AID - 10.1016/j.jns.2014.08.004 [doi]
PST - ppublish
SO  - J Neurol Sci. 2014 Nov 15;346(1-2):116-20. doi: 10.1016/j.jns.2014.08.004. Epub 
      2014 Aug 10.